JSPR · Jasper Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-07-16 |
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses |
| 2026-06-01 |
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous |
| 2026-05-14 |
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous |
| 2026-03-30 |
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous |
| 2026-02-24 |
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous |
| 2026-01-08 |
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median |
| 2026-01-07 |
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. |
| 2025-12-02 |
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces |
| 2025-12-01 |
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Webinar to be held Tuesday, December 2nd, at 8:00 am ET REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit |
| 2025-11-10 |
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous |
| 2025-11-04 |
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-12 | European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | Event |
| 2026-03-02 | 46th Annual TD Cowen Healthcare Conference | Conference |
| 2026-01-08 | Chronic Urticaria Data Update Webinar | Event |
| 2025-12-03 | 8th Annual Evercore Healthcare Conference | Conference |
| 2025-12-02 | ETESIAN Data + BEACON Investigation Webinar | Event |
| 2025-11-12 | TD Cowen Immunology & Inflammation Summit | Event |
| 2025-11-11 | Stifel 2025 Healthcare Conference | Conference |
| 2025-11-09 | UBS Global Healthcare Conference 2025 | Conference |
| 2025-09-09 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-09-03 | Cantor Fitzgerald Global Healthcare Conference 2025 | Conference |
Source: https://ir.jaspertx.com/